Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
about
Anticancer and cytotoxic properties of the latex of Calotropis procera in a transgenic mouse model of hepatocellular carcinoma.Anti-angiogenic peptides for cancer therapeuticsCancer treatment using peptides: current therapies and future prospectsIn Silico Design of Anticancer Peptides.MLACP: machine-learning-based prediction of anticancer peptides.
P2860
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
@ast
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
@en
type
label
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
@ast
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
@en
prefLabel
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
@ast
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
@en
P2093
P2860
P50
P356
P1476
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
@en
P2093
Christodoulos K
Deplanque G
Ganesan TS
Wellmann S
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602126
P407
P577
2004-11-01T00:00:00Z